ArticleAmerican journal of cancer research2023
Clinical efficacy of iodine-125 (
Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- Radioactive stent versus normal stent insertion for inoperable malignant biliary obstruction: a systematic review and meta-analysis.Surgical endoscopy · 2025Pooled it
- Clinical Outcomes and Individualized Seed Implantation Planning for Iodine-125 Seeds Brachytherapy in Lymph Node Metastases.Journal of Cancer · 2026Article
- Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma.Frontiers in endocrinology · 2026Article
- Efficacy and safety of anlotinib combined withFrontiers in endocrinology · 2025Observational
- Prediction of iodine-125 seed implantation efficacy in lung cancer using an enhanced CT-based nomogram model.PloS one · 2024Article
- Article
- The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) are resistant to radioactive iodine-131(
Indexed as
Identifiers
37970343PMC10636672W4388737172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.